Connor K M, Davidson J R T
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina 27710, USA.
Int Clin Psychopharmacol. 2002 Jul;17(4):185-8. doi: 10.1097/00004850-200207000-00005.
We assessed the efficacy and safety of a botanical anxiolytic, Kava kava (Piper methysticum), in treating generalized anxiety disorder (GAD). Thirty-seven adults with DSM-IV GAD were randomly assigned to 4 weeks of double-blind treatment with kava or a matching placebo. Weekly efficacy assessments [Hamilton Anxiety Scale, Hospital Anxiety and Depression Scale (HADS), Self Assessment of Resilience and Anxiety (SARA)] and safety evaluations were conducted. Improvement was observed with both treatments but no differences were found in the principal analysis. Post-hoc analyses revealed significant differences based on baseline anxiety severity, whereby kava was superior on the SARA in low anxiety and placebo was superior on the HADS and SARA in high anxiety. Both treatments were well tolerated. Although kava was not superior to placebo, it would be premature to rule it out as efficacious in GAD.
我们评估了一种植物性抗焦虑药卡瓦胡椒（Piper methysticum）治疗广泛性焦虑症（GAD）的疗效和安全性。37名符合《精神疾病诊断与统计手册》第四版（DSM-IV）标准的广泛性焦虑症成年患者被随机分配，接受为期4周的卡瓦胡椒或匹配安慰剂的双盲治疗。每周进行疗效评估[汉密尔顿焦虑量表、医院焦虑抑郁量表（HADS）、复原力与焦虑自我评估量表（SARA）]和安全性评估。两种治疗方法均观察到病情改善，但在主要分析中未发现差异。事后分析显示，根据基线焦虑严重程度存在显著差异，即卡瓦胡椒在低焦虑水平时在SARA量表上表现更优，而安慰剂在高焦虑水平时在HADS和SARA量表上表现更优。两种治疗方法耐受性均良好。虽然卡瓦胡椒并不优于安慰剂，但现在就将其排除在对广泛性焦虑症有效的药物之外还为时过早。
